ArriVent BioPharma, Inc. (AVBP): R&D Expense
$153.35M
Year ended 2025-12-31
$144.30M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $153.35M | +94.1% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $79.00M | +21.8% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $64.88M | n/a | 2025-03-03, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | $153.35M | +94.1% |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $90.40M | -13.1% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $142.01M | -17.1% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $129.64M | -25.3% |
| Liquidia Corp (LQDA) | 2025-12-31 | $39.28M | -17.9% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $13.18M | -32.7% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $134.85M | -39.4% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $158.68M | -7.5% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $60.26M | +5.2% |
Compare AVBP, AMLX, RCKT, KROS side by side · Screen every company in Pharmaceutical Preparations ↗